Business Context and Reporting Period
This Form 8-K is a current report filed by Biocardia, Inc. on September 22, 2025. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol BCDA. The filing reports a significant corporate event regarding regulatory progress in Japan.
Key Financial Metrics
This filing is an event-based report (Item 8.01) and does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. No financial data is included in this document.
Material Changes
The material change reported is a strategic regulatory milestone rather than a financial variance:
- Regulatory Consultation: Biocardia held a positive preliminary clinical consultation with Japan's Pharmaceutical and Medical Devices Agency (PMDA).
- Subject Matter: The consultation concerned the results of the CardiAMP Heart Failure Trial.
- Next Steps: The meeting was conducted in preparation for a formal clinical consultation regarding the acceptability of clinical data for a future application for approval.
Outlook, Risks, and Management Commentary
Management Commentary: The company characterizes the consultation as "positive," indicating progress toward regulatory approval in Japan. The filing references a press release (Exhibit 99.1) for further details.
Risks and Contingencies: While the consultation was positive, the filing notes that this is a preliminary step. The outcome of the formal clinical consultation and the subsequent approval application remains contingent on the PMDA's final review of the clinical data.
Investor Verification Checklist
- Review Exhibit 99.1 (the attached press release) for specific details on the PMDA's feedback and the timeline for the formal consultation.
- Verify the status of the CardiAMP Heart Failure Trial data package to understand the scope of the submission.
- Monitor future filings for the results of the formal clinical consultation and any subsequent regulatory decisions.
- Check the company's latest 10-Q or 10-K for current cash runway, as this 8-K does not disclose liquidity status.